Craft

Aurobindo Pharma

Stock Price

₹1.2 K

2024-05-28

Market Capitalization

₹717.2 B

2024-05-28

Revenue

₹246.2 B

FY, 2023

Aurobindo Pharma Summary

Company Summary

Overview
Aurobindo Pharma, a pharmaceutical company, manufactures and sells generic medicines to public and private health sectors in South Africa. The company’s product portfolio includes central nervous system, cardiovascular, pain, respiratory, anti-retroviral (for state tenders), metabolic, and anti-infective products. It markets and sells its products to health care professionals.A well integrated pharma company, Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations. Our customers include premium multi-national companies.. With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs from India.
Type
Public
Status
Active
Founded
1986
HQ
Hyderabad, IN | view all locations
Website
http://www.aurobindo.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • M. Madan Mohan Reddy

    M. Madan Mohan Reddy, Whole Time Director

  • K. Nityananda Reddy

    K. Nityananda Reddy, Vice Chairman and MD, Member

    • Avnit Bimal Singh

      Avnit Bimal Singh, Independent Director, Chairperson

      • Girish Paman Vanvari

        Girish Paman Vanvari, Independent Director, Chairperson, Member

        LocationsView all

        3 locations detected

        • Hyderabad, Telangana HQ

          India

          Hitech City Rd

        • South Brunswick Township, NJ

          United States

          6 Wheeling Rd, Dayton

        • Hyderabad, Telangana

          India

          Maitri Vihar Commercial Complex

        Aurobindo Pharma Financials

        Summary Financials

        Revenue (Q3, 2024)
        ₹72.7B
        Gross profit (Q3, 2024)
        ₹43.2B
        Net income (Q3, 2024)
        ₹9.4B
        Cash (Q2, 2024)
        ₹70.7B
        EBIT (Q3, 2024)
        ₹12.9B
        Enterprise value
        $713.0B

        Footer menu